1/9/2019
Nexvax2 Therapeutic Vaccine Fast-Tracked by FDA
ImmusanT, Inc., has announced that its therapeutic vaccine candidate, Nexvax2, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Continue ReadingImmusanT, Inc., has announced that its therapeutic vaccine candidate, Nexvax2, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Continue Reading[video width="600" height="200" mp4="/wp-content/uploads/2024/09/ICDS-2024-header-recap.mp4" poster="/wp-content/uploads/2024/09/ICDS-2024-header-recap.jpg"][/video] Last month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller led the End Points in Clinical Trials session, where...